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Twin arginine translocation (TAT)
BCG
MTBVACa b s t r a c t
Live vaccines are attractive vehicles for antigen delivery as a strategy to immunize against heterologous
pathogens. The live vaccine MTBVAC is based on rational attenuation of Mycobacterium tuberculosis with
the objective of improving BCG protection against pulmonary tuberculosis. However, the development of
recombinant mycobacteria as antigen-presenting microorganisms has been hindered due to their fastid-
ious genetic manipulation. In this study, we used MTBVAC as a genetic platform to deliver diphtheria,
tetanus, or pertussis toxoids, which are the immunogenic constituents of the DTP vaccine. When using
nonoptimal genetic conditions, the expression of these immunogens was barely detectable.
Accordingly, we pursued a rational, step-by-step optimization of the genetic components to achieve
the expression and secretion of these toxoids. We explored variants of the L5 mycobacteriophage pro-
moter to ensure balanced antigen expression and plasmid stability. Optimal signal sequences were iden-
tified by comparative proteomics of MTBVAC and its parental strain. It was determined that proteins
secreted by the Twin Arginine Translocation pathway displayed higher secretion in MTBVAC, and the
Ag85A secretion sequence was selected as the best candidate. Because the coding regions of diphtheria,
tetanus, and pertussis toxoids significantly differ in G + C content relative to mycobacterial genes, their
codon usage was optimized. We also placed a 3xFLAG epitope in frame with the C-terminus of these tox-
oids to facilitate protein detection. Altogether, these optimizations resulted in the secretion of DTP anti-
gens by MTBVAC, as demonstrated by western blot and MRM-MS. Finally, we examined specific antibody
responses in mice vaccinated with recombinant MTBVAC expressing DTP antigens.
 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccination is the public health intervention offering the best
cost-to-benefit ratio. Millions of lives are saved each year through
vaccination efforts; however, due to this silent benefit, the poten-
tial of vaccines is usually undervalued [1]. The advent of the
COVID-19 disease in 2019 (COVID-19), a pandemic that has now
surpassed 4 million deaths since December 2019 [2], has high-
lighted the clinical and social value of vaccines. The development
of new vaccine platforms based on messenger RNA (mRNA) or ade-noviral vectors has proven crucial to tackle the COVID-19 pan-
demic. These two vaccine strategies were initially developed
decades earlier as proof-of-concept against cancer and other infec-
tious diseases [3,4]. Exploration of classical and alternative vacci-
nation strategies is essential to endow research with the
technological arsenal to fight current, emerging and/or future
infectious diseases.
Tuberculosis (TB) is an infectious disease mainly caused by the
bacterium Mycobacterium tuberculosis, which killed 1.4 million
people in 2019, predominantly in developing countries [5]. This
high rate of mortality is reached despite the existence of the cente-
nary vaccine ‘‘Bacille de Calmette et Guérin” (BCG). BCG, the only
vaccine against TB currently in use, is a live vaccine consisting of
the causative agent of TB in cattle, Mycobacterium bovis, which
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between 1907 and 1921 [6]. Even if BCG is efficacious in preventing
severe forms of TB in children, it is less effective in preventing pul-
monary TB in adults. Thus, several vaccine candidates are being
developed to improve BCG. MTBVAC is a live attenuated vaccine
designed to replace BCG that has completed phase IIa dose-
finding trials in both adolescents and newborns in South Africa
(NCT02933281 and NCT03536117) [7]. Unlike BCG, which was
attenuated by random loss of chromosomal regions during subcul-
tivation, MTBVAC has been rationally attenuated by deletion of the
phoP and fadD26 genes involved in virulence [8–11]. Furthermore,
the MTBVAC parent strain (Mt103) is a human TB clinical isolate of
M. tuberculosis, which differs from the M. bovis cow pathogen used
to develop BCG [12]. Accordingly, MTBVAC maintains the whole T-
cell epitope repertoire of the human pathogen, including>25% of
these epitopes lost in BCG during subcultivation [13,14]. Alto-
gether, cumulative preclinical and clinical studies position
MTBVAC as a plausible new TB vaccine.
BCG has been historically proposed as a recombinant vaccine
vehicle to express heterologous antigens because of its exceptional
features [15]: it can persist for long periods inside macrophages,
inducing long-lasting humoral and cellular immune responses;
mycobacterial preparations exhibit intrinsic adjuvant properties,
and they are indeed the basis of Freund’s complete adjuvant; it is
safe for newborns; and it is low-cost compared with subunit vac-
cines. In addition, the existing paradigm in which vaccines only
protect against the target infection is being revisited [16] in light
of recent findings demonstrating that BCG protects against unre-
lated pathogens [17–19], resulting in fewer hospitalizations in
children [20] or reduced viral respiratory infections in the elderly
[21]. Taking into account that MTBVACmaintains or even improves
these properties of BCG [12,22], it would be of interest to evaluate
the suitability of MTBVAC as a vaccine delivery platform for
heterologous antigen expression.
In addition to the vaccine field, there is a need for new delivery
systems, or probiotics, to compose live biotherapeutics: the exist-
ing options, such as Escherichia coli, Bacteroides, and lactic acid
bacteria, are not able to stably colonize [23] or enter eukaryotic
cells. MTBVAC could serve as an alternative scaffold in synthetic
biology to deliver therapeutics inside host cells because it is cap-
able of persisting inside macrophages and nonphagocytic cells
[11,24]. However, synthetic biology toolkits in mycobacteria are
far from reaching the potential of E. coli, partly because of the slow
growth rate of M. tuberculosis, its poor DNA uptake, and its high
rate of illegitimate recombination [25]. Despite these obstacles, a
variety of genetic tools for mycobacteria have been developed,
such as integrative and replicative plasmids, reporter systems,
inducible and wide range strength promoters, selectable markers
[26], recombineering [27], or even CRISPR-based [28,29] method-
ologies. However, to our knowledge, these methods have not been
integrated into synthetic biology studies in M. tuberculosis. In this
study, we used MTBVAC as an M. tuberculosis derivative to pave
the way for synthetic biology in this fastidious pathogen.
In a first attempt to test the ability of MTBVAC to express
heterologous antigens, we used the p2auxoHIVA plasmid, previ-
ously tested in BCG, to express and secrete human immunodefi-
ciency virus (HIV) epitopes in lysine-auxotrophic MTBVAC. We
achieved the expression of HIV epitopes in auxotrophic MTBVAC,
which induced a specific immune response against those epitopes
[30]. This proof-of-concept study supported the use of MTBVAC as
an antigen delivery platform.
Regarding the heterologous antigens to be expressed, here, we
used diphtheria, tetanus, and pertussis toxoids, which are the
immunogenic constituents of the DTP vaccine. These immunogens
were selected based on the observation that BCG or MTBVAC
administered before the DTP vaccine was able to trigger Th14274immune responses against diphtheria, tetanus, and pertussis in
mice. Immunization with DTP alone elicited a Th2 or a Th1/Th2
response. In addition, antibody responses against DTP antigens
were also enhanced by previous immunization with BCG or
MTBVAC in mice [31].
Genetic inactivation of diphtheria and pertussis toxins has been
described without loss in their immunogenicity, while fragment C
of the tetanus toxin is immunogenic with no associated toxicity.
While genetic inactivation makes DTP toxoids ideal for recombi-
nant expression in MTBVAC, clinical features could also be rele-
vant. The DTP vaccine efficiently protects against tetanus and
diphtheria, but protection against whooping cough caused by
Bordetella pertussis remains less than optimal [32]. Recently, mater-
nal immunization with pertussis vaccines and transplacental
transfer of maternal antibodies have helped to diminish whooping
cough cases in newborns, who are the most vulnerable population
[33].
Altogether, based on this previous evidence, we hypothesize
that constructing a recombinant MTBVAC expressing and secreting
the DTP constituents would not only enhance immune responses
against these immunogens but also pave the way to develop a
combined vaccine against TB, diphtheria, tetanus, and pertussis.
This latter possibility opens interesting avenues for live vaccines
in terms of reducing vaccine production costs. The use of lyophi-
lized microorganisms can avoid the need for cold chain distribu-
tion in developing countries or afford a combined, long-term
immunization with a single shot.2. Material and methods
2.1. Bacteria
The Escherichia coli HST08 (StellarTM; Clonetech) strain, used for
cloning steps, was grown at 37 C in Luria-Bertani (LB) broth or on
agar plates supplemented with kanamycin (km; 20 lg/mL) when
necessary.
M. tuberculosis MTBVAC (Universidad de Zaragoza) and its
derived strains were grown at 37 C in Middlebrook 7H9 broth
supplemented with albumin-dextrose-catalase (ADC) 10% and
with 0.05% (v/v) Tween-80 (7H9T-ADC). When necessary, MTBVAC
was cultured on solid Middlebrook 7H10 plates supplemented
with 0.5% glycerol and 10% ADC. When required, km was added
at a concentration of 20 lg/mL. Bacterial suspensions for vaccina-
tion were prepared by diluting frozen PBS stocks previously quan-
tified by plating serial dilutions.2.2. Construction of MTBVAC-pJKB7, MTBVAC-pJKD6 and MTBVAC-
pJKC1
pJKB7, pJKD6, and pJKC1 plasmids were previously generated
[34]. Electrocompetent MTBVAC was prepared as follows: bacterial
cultures at an optical density at 600 nm of 0.6–0.8 were supple-
mented with glycine at 0.2 M and incubated at 37 C for 24 h. Then,
bacteria were pelleted and washed twice with 0.05% Tween-80 and
once with 10% glycerol-0.05% Tween-80 and finally suspended in
1/100 of the initial culture volume of 10% glycerol-0.05% Tween-
80. Aliquots of 200–400 lL were electroporated with 0.5–1 lg of
replicative pJKB7, pJKD6, and pJKC1 plasmids. Gap cuvettes
(0.2 cm) (Bio-Rad) were used with a single pulse (2.5 kV, 25 lF,
1000 X) in a GenePulser XcellTM (Bio-Rad). Cells were recovered
on 7H9T-ADC and incubated for 24 h at 37 C to express antibiotic
resistance genes. Then, serial decimal dilutions were plated on
7H10 plates containing the appropriate antibiotic. Colonies typi-
cally appeared in 3–4 weeks.
Fig. 1. Optimization of the L5 mycobacteriophage promoter for use in M. tuberculosis. A. Vector (pJK) for heterologous antigen expression in mycobacteria. The locations and
directions of the gfp and kanamycin resistance (km) genes are indicated. This vector contains pAL5000 and pBR322 replicative origins for mycobacteria and E. coli,
respectively. The L5 mycobacteriophage-derived promoters (C1, D6 and B7) are located upstream of gfp. NdeI and ClaI cloning sites are indicated. B. Partial sequences of the
C1, D6 and B7 L5 mycobacteriophage promoters used in this study. The 35 and 10 boxes, as well as the transcription start site (TSS), are indicated. Note the different
nucleotide polymorphisms spanning the promoter length in each variant. C. Liquid cultures of MTBVAC transformed with the plasmid depicted in panel A carrying C1, D6 and
B7 promoters. Note the green colouration of the cultures resulting from GFP expression from the D6 and B7 promoters. D. Whole-cell fractions of cultures depicted in panel C
stained with Coomassie blue dye. Note that the prominent band at 25 kDa is compatible with the molecular weight of the GFP protein. E. Relative fluorescence of MTBVAC
strains carrying the gfp gene controlled by either the C1, D6 or B7 promoter. These promoters show different strengths ranging from high (D6) to medium (B7) and low (C1),
which are maintained during the 35 days of the experiment. Statistical analysis was performed using the Friedman test followed by Dunn’s multiple comparison test using
MTBVAC as a control. Asterisks indicate the following p-values: *= 0.05 > p > 0.01; **=0.01 > p > 0.0005. F. Cytometry measurements of GFP activity in bacterial populations
carrying the gfp gene under the control of C1, B7 and D6 promoters. The diagram indicates GFP measures in cultures with antibiotic (km + ) pressure or cultures after seven
passages without antibiotic (7p. km-). Note the gradual loss of plasmids with the D6 and B7 promoters in contrast to the stability of the plasmid bearing the C1 promoter. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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To generate the pJKD6ssXGFP plasmid (Fig. 2C), where X repre-
sents the different signal sequences (ss), DNA fragments containing
the ss of ssag85A, ssag85B, ssag85C, ssblaC, ssrv0180c, ssrv0203,
ssrv1987, and sscfp10 were amplified by PCR from MTBVAC geno-
mic DNA. The oligonucleotides used are listed in Supplementary
Table 1 as pJKD6ssX_fw and GFPssX_rv, except in the case of sscf-
p10, in which ss was cloned after the gfp gene in the BsrGI cloning
site. These PCR fragments were cloned in the pJKD6 plasmid previ-
ously digested with NdeI or ClaI by using an In-Fusion cloning kit
(TaKaRa) system that allows ligase-independent cloning. E. coli
Stellar was transformed with the reaction product, and proper
recombination was checked by PCR and Sanger sequencing.
MTBVAC was electroporated with pJKD6ssXGFP derivatives as pre-
viously described.2.4. Construction of rMTBVACss-FC, rMTBVACssCRM and rMTBVACssS1
strains
The pJK-derived plasmids containing the signal sequence of
Antigen 85A and the codon-optimized genes for FC, CRM197,
or S1 were synthesized and subcloned into NdeI-ClaI sites
by Genscript Company (Piscataway, USA). A schematic repre-
sentation of the pJK derivatives is shown in Fig. 3A. MTBVAC
was electroporated with pJK derivatives as previously
described.42752.5. Construction of rMTBVAC-FC, rMTBVAC-CRM and rMTBVAC-S1
strains
To generate pJK plasmids without signal sequences (Fig. 3E),
DNA fragments containing S1, FC, or CRM197 with optimized
codons were amplified from pJKD6ssA-S1, pJKD6ssA-FC, or
pJKD6ssA-CRM by PCR. These PCR fragments with exactly 15 bp
identity to pJKD6 were inserted into pJKD6 previously digested
with NdeI and ClaI. The correct construction checked by PCR and
by Sanger sequencing was electroporated into MTBVAC.2.6. Protein extraction
Intracellular protein extracts of mycobacteria were prepared
from late log-phase cultures grown in 7H9T-ADC. Cells from
50 mL of culture were pelleted by centrifugation (4,000 g for
10 min at 4 C). Mycobacterial cell pellets were washed twice with
PBS to remove albumin and then resuspended in 1 mL of cold PBS.
Mycobacterial suspensions were disrupted by sonication using the
BioRuptor (Diagenode) for 15 min (30 s pulse at high power),
allowing cooling in an ice-water bath for 30 s between pulses.
The samples were centrifuged at 4000 g for 10 min at 4 C, and
the supernatant containing whole-cell protein extracts was filtered
through a 0.22 lm-pore-size low protein-binding filter (Pall).
For extraction of secreted proteins, mycobacterial strains were
cultured in 7H9T medium supplemented with dextrose, NaCl,
and catalase in the absence of albumin. Cultures were grown until
Fig. 2. Selection of an optimized signal sequence to secrete heterologous antigens in MTBVAC. A. Images from 2D-DiGE gels showing the secreted proteomes of the Mt103
strain (labelled in green), the MTBVAC vaccine (labelled in red) and the merged image. Note the predominant secretion of ESAT-6 and CFP-10 in Mt103 relative to MTBVAC.
Additionally, note the increased secretion of the Ag85 complex in MTBVAC relative to Mt103. B. Western blot of Ag85A, 85B, 85C and ESAT-6 proteins in secreted fractions of
Mt103 and MTBVAC. C. Construction of a reporter vector of protein secretion in mycobacteria. The plasmid in panel 1A was cut with NdeI, and the secretion signals of Ag85A,
85C and Rv1987 were introduced upstream of the coding sequence of the gfp gene. The secretion signal of CFP-10 was cloned into the ClaI site. D. Characteristics of the Ag85A,
85C and Rv1987 secretion signals. The hydrophilic profile of each residue and the RR motif of the TAT secretion pathway are indicated. The downside arrow indicates the
putative processing site. E. Relative fluorescence unit (RFU) measurements of secreted and whole-cell fractions of MTBVAC transformed with plasmids indicated in panel C.
Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparison test using MTBVAC as the control group. Asterisks indicate the
following p-values: * 0.05 > p > 0.01; **** 0.0001 > p. Note that GFP was successfully secreted with each signal secretion tested, and the Ag85A secretion signal resulted in the
best secretion efficacy. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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The supernatant was filtered through a 0.22 lm-pore-size low
protein-binding filter (Pall). The extracellular proteins were precip-
itated for 1 h at 4 C with 10% v/v trichloroacetic acid. Next, pellets
were collected by centrifugation (4000 g, 1 h at 4 C), washed with
cold acetone, and resuspended in 200 lL of 150 mM Tris-HCl pH
8.8. In both cases, proteins were quantified using the QuantiPro
BCA assay (Sigma-Aldrich) and stored at 80 C.
2.7. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Ten micrograms of each protein extract was boiled for 5 min in
the presence of 3 lL of 150 mM Tris/HCl pH 7.4, 3% SDS, 0.3 mM
sodium molybdate, 30 mM sodium pyrophosphate, 30 mM NaF,
30% glycerol, 30% mercaptoethanol and 0.06% bromophenol blue.
Then, proteins were separated by electrophoresis through a 5%
stacking gel over a 10–15% resolving polyacrylamide gel containing
0.1% SDS in running buffer (25 mM Tris, 192 mM glycine, 3.4 mM
SDS) at a constant amperage of 30 mA/gel. PageRuler Plus Pre-
stained Protein Ladder (Thermo Scientific) was used as a molecular
weight marker. The gels were stained with NOVEX Coomassie col-
loidal (INVITROGEN).42762.8. Western blot
Proteins contained in SDS-PAGE gels without Coomassie
staining were transferred to PVDF membranes (preactivated
with methanol) in transfer buffer (48 mM Tris/HCl pH 8.3,
39 mM glycine, 0.037% SDS, 20% methanol) for 1 h at 20 V
with a semi-dry electrophoretic transfer cell (BioRad). The
membrane was blocked with 5% skim powdered milk in wash
buffer (0.9% (w/v) NaCl, 10 mM Tris/HCl pH 8.0, 0.1% Tween-
20) for 1 h at room temperature with mild shaking. Thereafter,
the membrane was incubated with primary antibody (Supple-
mentary Table 3) in wash buffer with 5% skim powdered milk
overnight at 4 C. Three washes with wash buffer were per-
formed before incubation with human serum adsorbed (HSA)
secondary antibodies conjugated with horseradish peroxidase
(HRP) in wash buffer with 5% skim powdered milk for 1 h
at room temperature and mild shaking. Then, the membrane
was washed again three times with wash buffer. Immunocom-
plex detection was performed by incubation with a chemilumi-
nescent HRP substrate (ImmobilonTM western, Millipore)
and subsequent exposure in a Proxima 2850 instrument
(Isogen).
Fig. 3. Experimental validation of rMTBVAC strains expressing or secreting DTP antigens. A. Construction of plasmids for heterologous antigen secretion in MTBVAC. The DNA
sequence for a protein consisting of the Ag85A secretion signal in fusion with each heterologous antigen (S1, FC or CRM197) and bearing a 3xFLAG epitope in the C-terminal
end was introduced into the NdeI and ClaI sites under the control of C1, D6 and B7 promoters. B. The tables represent the percentage of positive clones resulting from every
combination, where +++ indicates numerous colonies and – indicates no colonies. C. Schematic representation of the constructs selected from panel B to express and secrete
DTP antigens by rMTBVAC. D. Western blots of whole-cell and secreted fractions of rMTBVAC transformed with S1, FC and CRM197 secretion plasmids. The GroEL2 protein
was used either as a loading control in whole-cell samples or as a control in the absence of undesired lysis in secreted fractions, and wild-type MTBVAC served as the negative
control. Each DTP antigen was detected using an anti-FLAG antibody, allowing the detection of the fusion proteins. E. Schematic representation of the constructs used to
express DTP antigens in rMTBVAC, avoiding secretion toxicity. F. Western blots of whole-cell fractions of rMTBVAC carrying S1, FC or CRM197 expression plasmids. The
GroEL2 protein was used as an internal standard; control DTP antigens were detected using specific antibodies against S1 (PT), FC and CRM197 (DT). The first lane in every
panel corresponds to purified antigen protein. MTBVAC wild type serves as the negative control.
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The MRM assay approach was applied for the measurement of
specific peptides in complex mixtures. To detect S1, FC and
CRM197 in the rMTBVAC protein extracts, MRM/MS reactions were
performed by the Proteomics Facility of Servicios Científico Técni-
cos del CIBA (IACS-Universidad de Zaragoza). Cytosolic and
secreted protein extracts from rMTBVACs were electrophoretically
separated by SDS-PAGE. After staining with colloidal Coomassie
(INVITROGEN), the gel bands were cut, and these bands included
the adequate molecular weight of each antigen. For in-solution
digestion, purified toxins were dried in a speed-vac (Thermo) and
resuspended in denaturing buffer (6 M urea, 100 mM Tris-HCl
pH 7.8). Cysteines were reduced with 200 mM DTT for 30 min at
37 C and alkylated with 200 mM iodoacetamide for 30 min in
the dark. Unreacted iodoacetamide was consumed by adding
20 lL of the reducing agent (200 mM DTT) for 30 min at room tem-
perature. Samples were diluted with 25 mM ammonium bicarbon-
ate to a final concentration of less than 1 M urea. Partial digestion
was carried out with trypsin (Gold Trypsin, Promega) at a 1:50
ratio (enzyme/protein) for 3 h at 37 C. The reaction was stopped
by adding concentrated formic acid (Sigma). Protein bands from
the rMTBVAC samples were excised at an adequate molecular
weight from SDS-PAGE gels and washed with water, ammonium
bicarbonate (25 mM NH4HCO3), and acetonitrile. Next, samples
were reduced by incubation with dithiothreitol (10 mM) at 60 C
for 45 min and alkylated by incubation with iodoacetamide
(50 mM) at room temperature for 30 min. Finally, proteins were
trypsin digested overnight at 37 C with an enzyme:protein ratio
of 1:10 (Trypsin Gold, Promega). Digestion was stopped by the4277addition of 0.1% trifluoroacetic acid, and tryptic peptides were
extracted sequentially with increasing concentrations of acetoni-
trile in water. Samples were dried in a speed-vac (Thermo) and
reconstituted in 98% H2O, 2% acetonitrile, and 0.1% formic acid.
Protein identification was performed on a nano-LC system
(TempoMDLC, Eksigent, Dublin, CA, USA) coupled to a hybrid triple
quadrupole/linear ion trap mass spectrometer (4000 QTRAP, Sciex,
Foster City, CA). After precolumn desalting, tryptic digests (1 lg)
were separated on a C18 column (Acclaim PepMap100, 75 lm id,
15 cm, 3 lm particle size, Thermo Scientific, USA) at a flow rate
of 300 nL/min, with a 90 min linear gradient from 5 to 35% acetoni-
trile in 0.1% formic acid. The injection volume was 10 lL. The mass
spectrometer was interfaced with a nanospray source equipped
with an uncoated fused silica emitter tip (20 lm inner diameter,
10 lm tip, New Objective, Woburn, MA) and was operated in pos-
itive ion mode. MS source parameters were as follows: capillary
voltage 2800 V, source temperature 150 C, declustering potential
(DP) 85 V, curtain, ion source gas (nitrogen) 20 psi, and collision
gas (nitrogen) high. Analyses were performed using an
information-dependent acquisition (IDA) method with the follow-
ing steps: single enhanced mass spectra (EMS, 400–1400m/z) from
which the 8 most intense peaks were subjected to an enhanced
product ion [EPI (MS/MS)] scan. Once the 8 most intense ions were
subjected to downstream analysis, they were ignored for a period
of 25 s.
2.10. MRM analysis
The weight and migration parameters of each peptide were sta-
bilized to perform the MRM/MS technique with each purified
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from Calbiochem and fragment C of tetanus toxin kindly provided
by Dra. Rosario Osta and Diphtheria toxin (DT) from Calbiochem.
Optimal transitions were selected for each peptide with open-
source Skyline software (MacCoss Lab Software, Seattle, WA, ver-
sion 2.6.0.6851). Briefly, 3 to 5 transitions were selected for each
peptide based on the intensity of y-fragment ions in the MS/MS
spectra that were obtained in the LC-MS/MS analysis described
above. MRM analyses were conducted on the nano-LC system cou-
pled to the 4000QTRAP mass spectrometer with the same chro-
matographic and source parameter settings described above.
MRM transitions for each peptide were recorded with a dwell time
of 40 ms. Collision energies were automatically computed using
the embedded rolling collision energy equations of the Skyline
software. The mass spectrometer was instructed to switch from
MRM to enhanced product ion (EPI) scanning mode when an indi-
vidual MRM transition signal exceeded 1000 counts. Data were
analysed by submitting the MS/MS data to a MASCOT server (ver-
sion 2.3) (Matrix Science Ltd., London, UK). The data were searched
against the SwissProt M. tuberculosis sequence database supple-
mented with the sequences of PT, FC, and DT toxins. The identifica-
tion parameters were as follows: maximum missed cleavages 1,
fixed modifications carbamidomethyl (cysteines), peptide mass
tolerance 0.5 Da, fragment mass tolerance 0.3 Da.
2.11. 2D-DiGE (Differential in gel Electrophoresis)
Four independent cultures of Mt103 and MTBVAC were grown
in 7H9 0.05% Tween 80 supplemented with 0.2% dextrose and
0.085% NaCl. After 4 weeks of incubation at 37 C, cultures were
pelleted by centrifugation at 4000 g for 10 min. The supernatant
containing secreted proteins was incubated with 10% trichloroace-
tic acid (TCA) for one hour at 4 C and then centrifuged for 90 min
at 4000 g at 4 C. Pelleted proteins were incubated with cold ace-
tone for 2 h at 20 C and centrifuged for 30 min at 4000 g and
4 C, and the resulting pellet was air-dried for 15 min on ice. The
pelleted fraction of protein was resuspended in 200 lL DiGE label-
ling buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, Milli-Q
water). Protein sample pH was checked and adjusted to 9.5 with
KOH 1 N, quantified with the RC DC Protein Assay Kit (BioRad),
and protein integrity and absence of albumin contamination were
checked by SDS-PAGE and Coomassie staining. Secreted proteins
were analysed through fluorescence two-dimensional difference
gel electrophoresis (2D-DiGE). Briefly, Mt103 and MTBVAC sam-
ples were labelled with N-hydroxysuccinimidyl (NHS) ester deriva-Fig. 4. Immunization of mice with rMTBVAC expressing the FC tetanus antigen results in
selected for in vivo immunization that express DTP antigens by rMTBVAC, avoiding secr
female mice were immunized subcutaneously with 106 CFU of the corresponding rMTBV
as controls. Eight weeks later, the mice were euthanized, and blood was extracted for an
with rMTBVAC indicated in panel B carrying the constructs specified in panel A. The bar
vaccinated animals per vaccine group. Statistical analysis was performed using one-way A
group. Asterisks indicate **** 0.0001 > p-value.
4278tives of the cyanine dyes Cy3 and Cy5, respectively, and a pooled
internal standard of equal amounts of Mt103 and MTBVAC samples
was labelled with Cy2. These dyes provide different fluorescence
wavelengths for detection, allowing two or more differentially
labelled samples to be combined before being loaded onto an elec-
trophoresis gel. The three samples were separated in the first
dimension using isoelectric focusing (IPG strips pH 3–7) and in
the second dimension using standard SDS-polyacrylamide gel elec-
trophoresis (PAGE). Four different 2D-DiGE gels were prepared to
quantify differential protein secretion in the four biological repli-
cates of Mt103 and MTBVAC. For quantitative protein analysis,
2D-DiGE gels were exposed to different wavelengths, allowing
specific detection of cyanine dyes. The abundance of each protein
spot in a biological sample was measured as a ratio to its corre-
sponding spot in the internal standard, allowing a direct quantita-
tive comparison within each gel and normalizing abundance
values for every protein in each sample. A total of 315 proteins
showing significant differences between Mt103 and MTBVAC were
picked from 2D-PAGE gels and analysed by MALDI-ToF, resulting in
accurate identification of 24 proteins (Supplementary Table 1).2.12. Ethics
Mice were maintained in the regulated ‘‘Centro de Investiga-
ciones Biomédicas de Aragón” (CIBA, Zaragoza, Spain) facilities
with reference number ES 50 297 0012 011. The procedures were
carried out under Project Licence PI50/14 approved by the Ethics
Committee for Animal Experiments from the University of Zara-
goza. The care and use of animals were performed according to
the Spanish Policy for Animal Protection RD53/2013, which meets
the European Union Directive 2010/63 on the protection of animals
used for experimental and other scientific purposes.2.13. Animal studies
In all cases, 5- to 7-week-old female BALB/c mice were pur-
chased from Javier Labs. Groups of 5 female BALB/c mice were
immunized subcutaneously with a single dose of 100 lL containing
106 CFU of the corresponding recombinant MTBVAC expressing the
genetically inactivated toxins S1, CRM197, or FC. Saline
(phosphate-buffered saline) inoculation was used as a control
(Fig. 4). Blood was collected from immunized mice eight weeks
after immunization from heart punch in euthanized mice. Mice
were euthanized by CO2 exposure for 10 min.a specific anti-FC antibody response. A. Schematic representation of the constructs
etion toxicity. B. Experimental design of in vivo experiment. Groups of five BALB/c
AC expressing but not secreting S1, FC or CRM197, with MTBVAC wild type or saline
ti-S1, FC or CRM197 IgG evaluation. C. Specific IgG production in mice immunized
and error bars indicate the mean and standard deviation of antibody titers from five
NOVA followed by Dunnett’s multiple comparison test using MTBVAC as the control
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For cytometry studies of rMTBVAC-pJK expressing GFP, the bac-
teria were fixed with 4% paraformaldehyde. A Gallios flow cytome-
ter (Beckman) was used to determine the single-cell fluorescence
of gated bacterial cells based on the median fluorescein isothio-
cyanate signal (FITC; with 488-nm excitation and 500- to 560-
nm emission filters).2.15. Serum antibody measure ELISA
For determination of the specific anti-antigen IgG levels in
serum, MaxiSorp ELISA plates (NUNC) were coated with 1 lg/mL
of PT, TT or DT as previously mentioned, or with the standard curve
samples for calculating the IgG concentration (mouse reference
serum, Bethyl Technologies). The plates were incubated overnight
at 4 C. After a washing step with PBS-Tween 20 0.05% (v/v) buffer
(washing buffer), plates were blocked with incubation buffer
(bovine serum albumin 1% (w/v) in washing buffer) for 1 h at
37 C. Then, plates were incubated with 50 lL of proper serum
dilution for 90 min at 37 C. After three washes, plates were incu-
bated for 1 h at 37 C with goat anti-mouse IgG diluted 1:10,000
(KPL). After another three washes, plates were incubated for 1 h
at 37 C with HRP-conjugated rabbit anti-goat IgG diluted
1:10,000 (KPL). Finally, an enzyme-substrate reaction was devel-
oped using 3,30,5,50- tetramethylbenzidine (Sigma) as the sub-
strate, and the reaction was stopped with 0.1 N H2SO4. Optical
density was measured at 450 nm.3. Results
3.1. Classic genetic strategies are not suitable to express diphtheria,
tetanus, or pertussis toxoids in BCG or MTBVAC
As a first step, we envisaged a modular construction consisting
of each toxoid fused at the N-terminus to a signal secretion
sequence and controlled by a mycobacterial promoter (Supple-
mentary Fig. 1A). As signal sequences, we selected antigen (Ag)
85A (fbpA/Rv3804c) or Ag85B (fbpB/Rv1886c), which are well-
known secreted substrates in M. tuberculosis. As promoters, we
selected those from Ag85A, Ag85B, or Hsp60 (groEL2/Rv0440)
genes. The genetically inactivated sequences of pertussis (S1), teta-
nus (FC), and diphtheria (CRM197) toxins were cloned in frame
with each secretion sequence, and these sequences were placed
under the control of the different promoters. We generated 12 dif-
ferent modular constructs that were subsequently cloned in the
pMV361 integrative plasmid (Supplementary Fig. 1A). The result-
ing plasmids were checked by specific PCR (Supplementary
Fig. 1B) and Sanger sequencing and subsequently introduced into
MTBVAC or BCG by electroporation. In total, 12 recombinant
(rMTBVAC) and 12 recombinant BCG (rBCG) strains were
constructed.
The amounts of the S1, FC, and CRM197 mRNAs measured by
qRT-PCR revealed marginal expression levels compared to the sigA
endogenous gene (Supplementary Fig. 2A). Corroborating this find-
ing, western blots using specific antibodies raised against each
antigen showed undetectable antigen expression in most recombi-
nant strains, except weak S1 expression in 2 rBCG strains (Supple-
mentary Fig. 2B). This result is unexpected considering that the
sigA, fbpA, fbpB and groEL2 genes driven from their own promoters
showed robust mRNA expression levels in our previous RNA-seq
experiments [35]. Accordingly, we can hypothesize mRNA instabil-
ity in these constructs and decide to design another step-by-step
rationale strategy to optimize each genetic part of the constructs.42793.2. Promoters derived from the L5 mycobacteriophage allow tuning of
expression levels in M. tuberculosis
In a previous study, three different promoters derived from the
L5 mycobacteriophage were tested in BCG and Mycobacterium
smegmatis [34]. These promoters were placed upstream of the
enhanced green fluorescent protein (e-gfp) gene reporter in a
replicative shuttle plasmid containing the pAL5000 and pBR322
replication origins from mycobacteria and E. coli, respectively
(Fig. 1A). The different promoters showed nucleotide polymor-
phisms spanning the regulatory region and affecting the 10 box
and the transcription start site (TSS) (Fig. 1B). As a result, these
promoters demonstrated different strengths in BCG and M. smeg-
matis, ranging from high (B7), medium (D6) or low (C1) promoter
strengths, based on measures of GFP activity [34]. However, since
these promoters had not been tested in M. tuberculosis, we were
prompted to study their promoter activities in MTBVAC. Cultures
of transformed MTBVAC readily developed a green colour that
was visible by the naked eye, indicative of the high GFP expression
in the B7 and D6 transformants (Fig. 1C). This result was confirmed
by Coomassie staining of the total protein fraction of the MTBVAC
transformants, showing a prominent band in the range of 25 kDa
compatible with the molecular weight of the GFP protein
(27 kDa) (Fig. 1D). Next, we followed GFP activity for 35 days in liq-
uid cultures and observed that the D6 promoter showed higher
activity, followed by the B7 promoter, in MTBVAC (M. tuberculosis).
These results contrast with those results obtained in BCG and M.
smegmatis. The C1 promoter displayed lower activity in MTBVAC,
BCG, and M. smegmatis (Fig. 1E). Finally, we decided to investigate
plasmid stability in the absence of antibiotic pressure. rMTBVACs
transformed with the different plasmids were subcultured 7 times
in the absence of kanamycin. We observed that 38%, 66% and 95%
of MTBVAC cells containing the D6, B7 and C1 promoters, respec-
tively, maintained GFP fluorescence after 7 passages (Fig. 1F). This
result indicates that plasmid loss is proportional to promoter
strength. We hypothesize that the high GFP synthesis driven by
D6 and, to a lesser extent, B7 promoters might represent a meta-
bolic burden for MTBVAC. Altogether, characterization of promoter
strengths and plasmid stability are useful data to select the best
plasmid for every experiment. We should remember that the
rMTBVAC strains constructed in this study are intended for vacci-
nation experiments in animal models, where antibiotic pressure
does not exist. Accordingly, to ensure long-term plasmid stability
in vivo, the C1 promoter would be the preferred choice compared
to the B7 and D6 promoters.
3.3. Secretion signals of twin arginine Translocation substrates allow
efficient protein export in MTBVAC
To detect proteins differentially exported by MTBVAC compared
with the parental M. tuberculosis Mt103 strain, we performed a
proteomic comparison of the secreted protein fractions from these
strains. The results from 2D differential gel electrophoresis (DiGE)
revealed spots of differentially secreted proteins in M. tuberculosis
or MTBVAC (Fig. 2A). Those spots showing robust differential
secretion in four biological replicates were selected for protein
identification by MALDI-TOF. The most prominent, low molecular
weight bands with higher secretion in M. tuberculosis compared
to MTBVAC corresponded to ESAT-6 and CFP-10 (Fig. 2A), corrobo-
rating our previous findings [11,36–38]. Among the major proteins
secreted by MTBVAC, most putatively corresponded to proteins
secreted by the Twin Arginine Translocation (TAT) pathway (Sup-
plementary Table 2). Specifically, the most noticeable bands
secreted in MTBVAC were proteins from the Ag85 complex
(Ag85A, Ag85B, and Ag85C), which are also TAT-dependent sub-
strates (Fig. 2A). To confirm the results from 2D-DiGE, we analysed
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Mt103 and MTBVAC by western blot. The results showed a consis-
tently higher secretion of Ag85 proteins and absence of ESAT-6 in
MTBVAC (Fig. 2B). Once those proteins showing higher secretion in
MTBVAC were characterized, we decided to select an optimal sig-
nal sequence that allows heterologous protein secretion. We aimed
to place signal sequences from Ag85A, Ag85B, Ag85C, BlaC, Rv0203
and Rv1987 proteins upstream of the gfp gene, and these con-
structs were introduced under the control of the D6 promoter
(Fig. 2C). Of the attempted constructs, we successfully obtained
plasmids carrying the Ag85A, Ag85C and Rv1987 signal sequences,
which were characterized in terms of the presence of the twin-
arginine motif and their putative cleavage sites (Fig. 2D). As a
secreted protein internal control, we decided to use the CFP-10 sig-
nal sequence, which was previously demonstrated to be efficiently
secreted in MTBVAC [38,39]. It is important to note that the CFP-10
signal sequence was placed as a C-terminal fusion, unlike TAT sig-
nal sequences, which were placed as N-terminal fusions, to main-
tain the signal sequence locations of the original proteins. Next, we
analysed the secretion efficacy of the GFP protein fused to the
abovementioned signal sequences. We followed fluorescence in
the secreted and whole-cell fractions after 3, 9, and 13 days in liq-
uid culture. After examination of the normalized fluorescence data,
we concluded that Ag85A, Ag85C, and Rv1987 signal sequences
allow proper secretion of GFP and that this secretion increased
with time (Fig. 2E). The Ag85A secretion signal showed the best
secretion efficacy, even higher than CFP-10 (Fig. 2E), which is
prominently secreted by MTBVAC. In addition, of the three secre-
tion signals tested, only Ag85A showed significant differences in
either production or secretion of the reporter GFP protein.
3.4. Optimized coding genes of DTP toxoids placed under the control of
the Ag85A secretion signal allow heterologous protein secretion in
MTBVAC
In a final step, we aimed to design a modular construct to
achieve our objective of heterologous protein secretion in MTBVAC.
We used the previously characterized C1, B7 or D6 promoters to
ensure different expression levels (Fig. 1E). As a signal sequence,
we selected Ag85A, which showed the best secretion efficacy
(Fig. 2E). The S1, FC and CRM197 coding regions were placed in
fusion with the Ag85A signal peptide in their N-terminal ends
and to a 3xFLAG epitope in their C-terminal ends (Fig. 3A). This lat-
ter peptide allowed detection of the fusion protein by western blot.
It is important to note that S1, FC, and CRM197 toxoids were
derived from B. pertussis, Clostridium tetani, and Corynebacterium
diphtheriae, respectively, and that the G + C content of these bacte-
ria (67%, 28% and 53%, respectively) differed from that of M. tuber-
culosis (65%). Accordingly, the coding sequences of the toxoids
were optimized for codon usage in M. tuberculosis (Supplementary
Fig. 3A). After attempting to introduce these codon-optimized
sequences under the control of promoters with different strengths
into MTBVAC, we obtained the highest number of transformants
with the C1 promoter. These transformants also tested positive
by PCR (Fig. 3B). The transformants resulting from the D6 and B7
promoters were usually derived from small colonies and ulti-
mately resulted in false-positive clones (Fig. 3B). Altogether, we
continued with the molecular characterization of rMTBVAC
expressing the DTP toxoids under the C1 promoter. We aimed to
detect the specific production of DTP antigens by using specific
S1, FC and CRM197 antibodies. Since we were not able to detect
these proteins using the specific antibodies mentioned above (Sup-
plementary Fig. 4), with slight exception for FC, we used anti-FLAG
antibodies to specifically detect each toxoid fused with the 3xFLAG
epitope (Fig. 3D). Our results demonstrated the production of
recombinant proteins in the whole-cell and secreted fractions of4280rMTBVAC strains, indicative of proper secretion of these heterolo-
gous proteins into the culture supernatant (Fig. 3D). The specificity
of the antibody was confirmed by the lack of these bands in wild-
type MTBVAC. To further confirm the secretion of S1, FC, and
CRM197 toxoids in the rMTBVAC strains, we analysed secreted
fractions by multiple reaction monitoring (MRM), a highly specific
and sensitive label-free proteomic technique for identifying and
quantifying targeted proteins. The results demonstrated the secre-
tion of heterologous toxoids after the detection of a subset of speci-
fic peptides from the S1, FC, and CRM197 proteins (Supplementary
Fig. 5). Difficulties in obtaining positive clones derived from the D6
and B7 promoters (Fig. 3B) might indicate putative toxicity of TAT
secretion sequences placed under the control of a strong promoter,
probably by saturating the TAT machinery with high molecular
weight substrates carrying a TAT secretion signal. To prove this
hypothesis, we cloned the S1, FC and CRM197 codon-optimized
genes without a signal sequence under the control of the strong
D6 promoter (Fig. 3E). Remarkably, we obtained a high number
of transformants with this construct, which resulted in positive
clones after PCR verification (Fig. 3B). Additionally, these positive
clones showed efficient production of S1, FC, and CRM197 antigens
in rMTBVAC as detected by specific antibodies (Fig. 3F).3.5. Immunization of mice with rMTBVAC expressing or secreting the
FC antigen elicits a specific antibody response against tetanus toxoid
Once obtained the rMTBVAC strains which expressed, and/or
secreted our heterologous antigens, our goal was to demonstrate
that vaccination with these strains resulted in specific immune
responses. Unlike immunity against TB, which mainly relies on
cellular-mediated immune responses, protective responses against
DTP antigens are proportional to the levels of seroprotective anti-
bodies triggered after vaccination. Thus, we selectively focused
on the quantification of anti-DTP antibodies in the serum of vacci-
nated animals. Mice were immunized by the subcutaneous route
with wild-type MTBVAC as a control or rMTBVAC secreting S1,
FC or CRM197 toxoids whose expression was controlled by the
C1 promoter. Eight weeks after immunization, blood was collected
from the immunized mice to detect specific antibodies in the
serum. Using these constructs, we did not detect anti-S1, anti-FC
or anti-CRM197 responses, probably due to low antigen secretion
levels in rMTBVAC. Then, we decided to immunize mice with
rMTBVAC-producing but not rMTBVAC-secreting S1, CRM197,
and FC toxoids from the D6 promoter. We previously verified that
these rMTBVAC strains expressed high amounts of DTP antigens
without producing toxicity (Fig. 3F). Our results confirmed a speci-
fic anti-FC response in mice immunized with the recombinant vac-
cine expressing the FC tetanus fragment (Fig. 4), which correlates
with robust expression of the FC antigen in the corresponding
rMTBVAC strain. Altogether, we have demonstrated that recombi-
nant vaccines based on MTBVAC are able to elicit dose–response
antibody responses against heterologous antigens after a single
dose, and our results pave the way for future optimization of this
vaccine platform.4. Discussion
4.1. Suitability of live TB vaccines as genetic platforms to express
heterologous proteins
Vaccination, antibiotics, clean water, and sanitation are among
the most effective public health interventions that have prevented,
or even eradicated, infectious diseases that once killed millions of
people. Accordingly, the prevention of current, emerging, or future
infectious diseases through vaccination has the potential to make
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Today, the World Health Organization lists 25 vaccine-
preventable diseases [40], and many others are in development.
Some of these vaccines are administered in combinations to confer
immunity against diverse pathogens with a single shot. Accord-
ingly, vaccinology benefits not only from the investigation of
new vaccine candidates but also in developing new vaccine combi-
nations, or even in designing recombinant live vaccines able to
express the immunogenic constituents from other vaccines.
Although some bacteria have been proposed as vaccine vehicles,
it is important to note that none of these bacteria are currently
used in vaccination policies, with the notable exception of BCG
[41].
BCG is a centenary vaccine highly efficacious in preventing sev-
ere TB in infants. However, since BCG has limitations in preventing
TB in adults, new vaccines are being investigated. Most of the TB
vaccines in the pipeline are based on subunits or inactivated vac-
cine candidates, and live TB vaccines are limited to BCG revaccina-
tion, rBCG, or the attenuated MTBVAC vaccine [42]. MTBVAC
presents some advantages relative to BCG: it is based on the
human pathogen M. tuberculosis [38]; it maintains all epitopes pre-
sent in M. tuberculosis [13], including those lost in BCG; it secretes
higher amounts of immunodominant antigens compared to BCG;
and it is produced in uniform clinical lots, avoiding the risk of
the emergence of ‘‘daughter strains” as happened with BCG. Fur-
thermore, recent animal studies have demonstrated that MTBVAC
confers a significant improvement, compared to BCG, in protecting
rhesus macaques against an aerosol challenge with M. tuberculosis
[43] and that MTBVAC protects mice against the most widely dis-
tributed M. tuberculosis lineages in the human population [38].
These advantages are endorsed by the successful results in phase
I and IIa clinical trials [7,44].
We have previously demonstrated that MTBVAC persists for
several weeks in the lymph nodes of vaccinated mice [11], and con-
sequently, we hypothesize that MTBVAC-based immunization
could stimulate host immunity during a long-term period. In addi-
tion, MTBVAC maintains or even improves the beneficial nonspeci-
fic effects documented for BCG [12]. Taken together, these
observations highlight the potential of MTBVAC as a vaccine plat-
form to synthesize unrelated antigens to afford combined protec-
tion against TB and unrelated diseases.
4.2. The rationale to express DTP antigens in MTBVAC
In this study, we sought to construct rMTBVAC expressing and
secreting DTP antigens. This rationale is based on our previous
findings demonstrating that vaccination of mice with BCG or
MTBVAC before vaccination with DTP results in higher antibody
and Th1 responses than vaccination with DTP alone. Furthermore,
exploration of human epidemiological data showed that pertussis
incidence was 10-fold lower in countries that use DTP and BCG
than in countries that use only DTP, supporting the hypothesis of
a nonspecific immune enhancement of BCG favouring the DTP
immune response [31]. Additionally, it is estimated that preven-
tion of diphtheria, tetanus, and pertussis largely benefits from
the 85% coverage of the different DTP vaccines available, and
immunization with BCG against TB reached >90% vaccine coverage
in 2019 [45]. Because BCG and DTP have similar vaccination cover-
ages, a combined TB and DTP vaccine would offer benefits in terms
of lower production, distribution, and administration costs.
The period between birth and the first DTP immunization is
usually two months, and it is critical for newborns: they are not
protected against diphtheria, tetanus, or whooping cough, and this
is when most pertussis cases occur [46]. Since vaccines against TB
are administered at birth, vaccination with rMTBVAC expressing
DTP antigens could help to cover this window of susceptibility.4281Moreover, DTP vaccination requires at least 3 doses to achieve ade-
quate protection. Since MTBVAC persists for long periods in vacci-
nated mice [11], the production of recombinant DTP antigens by
rMTBVAC would result in a constant presentation of these antigens
to the immune system and might reduce the number of DTP doses
required for maximum protection.
Although previous works have attempted to construct rBCG
vaccines expressing either pertussis or diphtheria antigens [47–
49], to our knowledge, this is the first study to demonstrate the
feasibility of expressing and secreting the three DTP antigens in a
live TB vaccine. In addition, since we have used the M. tuberculosis
derivative MTBVAC, this work aims to establish the basis for syn-
thetic biology in the Mycobacterium genus.
4.3. Challenges and perspectives for heterologous protein expression in
Mycobacterium
Even if the arsenal of mycobacterial genetic tools is continu-
ously growing, it does not necessarily reach the potential and ver-
satility of genetic manipulation in other model organisms, such as
Escherichia coli. In addition, the construction of recombinant
mycobacteria is hampered due to the fastidious growth and
pathogenicity of these microorganisms. Indeed, the use of classic
molecular genetic tools in BCG or MTBVAC resulted in negligible
expression of S1, FC and CRM197 (Supplementary Fig. 1). Remark-
ably, we obtained these negative results after a combination of
three different promoters, two signal secretion sequences, and
three genes coding heterologous proteins (Supplementary Fig. 1).
The fact that DTP and other antigens have been efficiently
expressed in BCG using comparable tools [48–51] reinforces the
notion that heterologous expression in M. tuberculosis is not trivial.
After optimization of each genetic part of the construction fol-
lowing a rational process, we succeeded in the expression and
secretion of the three DTP antigens in the M. tuberculosis derivative
MTBVAC. Our results indicated conclusions that could be of inter-
est for future synthetic biology approaches in M. tuberculosis. First,
the promoter strength was inversely proportional to vector stabil-
ity in the absence of selective pressure (Fig. 1D,E,F). This is a key
observation for infection or vaccination experiments in animal
models, where selective pressure for plasmid maintenance is usu-
ally absent. Second, signal secretion sequences from the Ag85A and
CFP-10 proteins placed at the N- and C-terminal ends, respectively,
are suitable candidates for protein secretion in M. tuberculosis
(Fig. 2E). Remarkably, the signal peptides of Ag85A and CFP-10 pro-
teins are recognized by two different secretion systems, namely,
TAT and ESX-1, respectively [52,53], which provides versatility to
achieve protein secretion in M. tuberculosis. Third, higher secretion
of TAT substrates in MTBVAC is probably related to the phoP gene
mutation in this vaccine. A previous transcriptomic comparison of
M. tuberculosis and its phoPmutant demonstrated that a noncoding
RNA,mcr7, is the more regulated RNA from the PhoP regulon. Mcr7
post-transcriptionally regulates translation of the tatC gene, which
is a constituent of the TAT machinery [34]. Consequently, TAT-
exported proteins show higher secretion in M. tuberculosis phoP
mutants [38]. Fourth, the use of a strong promoter is incompatible
with secretion signals of the TAT secretion pathway. We hypothe-
size that the high expression of high molecular weight proteins
bearing a TAT secretion signal might result in saturation of the
TAT machinery. It is plausible that the efficiencies of transcription,
translation, and secretion processes should be tightly orchestrated
through an appropriate combination of promoters, ribosome bind-
ing sites, and signal peptides, as documented in other bacteria [54].
Fifth, considering the 65% G + C content in mycobacteria, codon
optimization is recommended for the heterologous expression of
proteins from non-mycobacterial species. Sixth, a 3xFLAG epitope
placed in the C-terminal end of our constructs resulted in a versa-
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approach might be even more useful to detect synthetic proteins
or in cases where there are no commercial antibodies available.
Seventh, high levels of antigen production are necessary to induce
an antibody response in vivo. In rBCG, this has also been shown for
pneumococcal antigens, and secretion/exportation increased the
antibody response [55]. Eighth, antigens expressed in rMTBVAC
can induce an antibody response even if they are not secreted
in vitro. This has also been observed with rBCG-DTP antigens,
where both CRM197 and FC (cell wall and cytosolic localization)
induced specific antibody formation [49,50]. Altogether, we have
paved the way to design an engineered TB vaccine platform for
the expression of unrelated proteins.
We should bear in mind that the efficacy of genetic tools does
not necessarily correlate across mycobacterial species. As an exam-
ple, the L5 mycobacteriophage promoters used in this study show
different strengths depending on the genetic backgrounds [34].
Other evidence comes from the observation that during the con-
struction of rBCG-DTP vaccines, the exportation of the antigens to
the cell wall was achieved for S1 and CRM197 but not for FC. In
these studies, exportation was intended through use of the
b-lactamase promoter and signal sequence, indicating that the
secretion efficacy of this signal sequence depends on the antigen
[48–50]. In summary, sincemost genetic tools have been developed
either for fast-growing M. smegmatis or M. bovis-derived
BCG, endeavors should be devoted to adapt these tools to the
M. tuberculosis pathogen.
4.4. Future prospects for live TB vaccines
Vaccinology is an evolving science. The first attempts of Edward
Jenner and Louis Pasteur to develop attenuated smallpox and
rabies vaccines were soon followed by the discovery that immu-
nization with toxoids or inactivated microorganisms protected
against diphtheria, tetanus or whooping cough. Recently, the
development of cell culture and recombinant DNA technologies
has allowed the design of vaccines against a variety of bacteria
and viruses [56]. The 21st century has projected novel technologies
such as reverse vaccinology, which has resulted in vaccines against
type B meningitis, or the recent advent of adenoviral vectors or
mRNA vaccines [57].
In this study, we propose a complementary approach through
the use of attenuated vaccines as bacterial factories to produce
the immunogenic constituents of other proof-of-concept vaccines.
This approach is limited to live attenuated vaccines such as the
typhoid vaccine, the TB vaccine BCG, or BCG-replacement strate-
gies such as MTBVAC. The development of live vaccine factories
opens interesting perspectives in terms of multivalent immuniza-
tion, persistent presentation of the antigen to the immune system,
or its preparation as lyophilized formulations. In addition to health
benefits, the combination of multiple immunizations in a single
vaccine allows lower costs in terms of production, distribution
and personnel required for administration. We should also remem-
ber that live TB vaccines confer a plethora of beneficial, nonspecific
effects [58] such as protecting against unrelated pathogens [18,22]
through priming trained immunity [59] or enhancing the immu-
nity of unrelated vaccines [31]. Taken together, these heterologous
effects of live TB vaccines together with the potential to construct
recombinant derivatives open exciting perspectives for next-
generation vaccine strategies.
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